Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05854498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 32 days later Jul 2028 → Sep 2028
See other at-risk trials from University of Wisconsin, Madison

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 2028 to Sep 2028
    • Study completion pushed from Jul 2028 to Dec 2028
    • Eligibility criteria expanded, about 10 words
    • Study description expanded, about 4 words
  2. Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 25 to 50
    • Primary and study completion dates: Jul 2026 to Jul 2028
    • Site details revised
    v10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  4. 2 versions Re-verified since May 20, 2024, no change to tracked fieldsv7-v8
  5. Start date changed from estimate of Oct 2023 to Oct 13, 2023v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2023 to Oct 2023
    • Site details revised
    v5
  2. Start date: Aug 2023 to Sep 2023v4
  3. Start date: Jul 2023 to Aug 2023v3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
Trial Details
NCT Number NCT05854498
Lead Sponsor University of Wisconsin, Madison
Collaborators: Ipsen
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov